Symbols / ACON $3.57 +4.69% Aclarion, Inc.
ACON Chart
About
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Health Information Servi | Market Cap | 8.15M |
| Enterprise Value | -3.88M | Income | -7.24M | Sales | 75.73K |
| Book/sh | 15.02 | Cash/sh | 5.27 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -0.26 | PEG | — |
| P/S | 107.59 | P/B | 0.24 | P/C | — |
| EV/EBITDA | 0.57 | EV/Sales | -51.20 | Quick Ratio | 14.40 |
| Current Ratio | 14.81 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -13.61 | EPS next Y | -13.71 | EPS Growth | — |
| Revenue Growth | 80.60% | Earnings | 2026-03-18 16:00 | ROA | -55.81% |
| ROE | -104.80% | ROIC | — | Gross Margin | 9.02% |
| Oper. Margin | -107.85% | Profit Margin | 0.00% | Shs Outstand | 2.28M |
| Shs Float | 2.04M | Short Float | 13.54% | Short Ratio | 1.99 |
| Short Interest | — | 52W High | 12.03 | 52W Low | 2.34 |
| Beta | 1.14 | Avg Volume | 876.53K | Volume | 56.24K |
| Target Price | $7.00 | Recom | Strong_buy | Prev Close | $3.41 |
| Price | $3.57 | Change | 4.69% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-25 | main | Ascendiant Capital | Buy → Buy | $7 |
| 2025-11-20 | main | Ascendiant Capital | Buy → Buy | $23 |
| 2025-09-19 | main | Ascendiant Capital | Buy → Buy | $22 |
| 2024-12-13 | down | Maxim Group | Buy → Hold | — |
| 2024-11-27 | main | Ascendiant Capital | Buy → Buy | $1 |
| 2024-08-26 | main | Ascendiant Capital | Buy → Buy | $2 |
| 2024-07-29 | init | Ascendiant Capital | — → Buy | $2 |
- Aclarion (NASDAQ: ACON) seeks stockholder approval to expand equity plan to 500,000 shares - Stock Titan Fri, 03 Apr 2026 21
- ACON Stock Pops 45% Pre-Market Today: What’s Driving The Move? - Stocktwits hu, 08 Jan 2026 13
- New Analyst Forecast: $ACON Given $7 Price Target - Quiver Quantitative Wed, 25 Mar 2026 10
- ACON Should I Buy - Intellectia AI hu, 02 Apr 2026 07
- Why Is Aclarion Stock (ACON) Up Today? - TipRanks hu, 08 Jan 2026 08
- Aclarion installs 1-year takeover defense, keeps door open to fair bids - Stock Titan hu, 19 Mar 2026 07
- $ACON stock is up 38% today. Here's what we see in our data. - Quiver Quantitative hu, 08 Jan 2026 08
- Aclarion targets US insurers as back-pain trial readout nears - Stock Titan hu, 19 Mar 2026 07
- Aclarion, Inc. Stock (ACON) Opinions on Nociscan Technology Publication | ACON Stock News - Quiver Quantitative hu, 04 Dec 2025 08
- Back pain imaging firm Aclarion courts partners at LSI USA 2026 - Stock Titan hu, 12 Mar 2026 07
- Aclarion, Inc. Secures $10.4 Million in Common-Stock Financing to Strengthen Balance Sheet and Extend Operating Runway - Quiver Quantitative ue, 13 Jan 2026 08
- Debt-free Aclarion now holds $21.6M to grow its AI back pain tool - Stock Titan ue, 13 Jan 2026 08
- Aclarion, Inc. to Engage with Investors at the 38th Annual ROTH Conference Regarding Nociscan Advancements - Quiver Quantitative ue, 17 Mar 2026 10
- Back pain scan firm Aclarion meets investors at ROTH with no debt - Stock Titan ue, 17 Mar 2026 07
- Back pain scans jump 69% as Aclarion extends its cash runway into 2027 - Stock Titan hu, 08 Jan 2026 08
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.08
+65.62%
|
0.05
-39.36%
|
0.08
+24.75%
|
0.06
|
| Operating Revenue |
|
0.08
+65.62%
|
0.05
-39.36%
|
0.08
+24.75%
|
0.06
|
| Cost Of Revenue |
|
0.07
-18.61%
|
0.08
+11.79%
|
0.08
+15.97%
|
0.07
|
| Reconciled Cost Of Revenue |
|
0.07
-18.61%
|
0.08
+11.79%
|
0.08
+15.97%
|
0.07
|
| Gross Profit |
|
0.01
+117.54%
|
-0.04
-11916.67%
|
-0.00
+93.33%
|
-0.00
|
| Operating Expense |
|
7.06
+28.96%
|
5.47
+12.25%
|
4.88
-12.25%
|
5.56
|
| Research And Development |
|
1.03
+16.32%
|
0.89
+1.77%
|
0.87
-18.23%
|
1.07
|
| Selling General And Administration |
|
6.03
+31.41%
|
4.59
+14.57%
|
4.00
-10.84%
|
4.49
|
| Selling And Marketing Expense |
|
1.90
+94.62%
|
0.98
+29.00%
|
0.76
+52.01%
|
0.50
|
| General And Administrative Expense |
|
4.12
+14.30%
|
3.61
+11.20%
|
3.25
-18.68%
|
3.99
|
| Other Gand A |
|
4.12
+14.30%
|
3.61
+11.20%
|
3.25
-18.68%
|
3.99
|
| Total Expenses |
|
7.13
+28.23%
|
5.56
+12.24%
|
4.95
-11.92%
|
5.62
|
| Operating Income |
|
-7.05
-27.92%
|
-5.51
-13.04%
|
-4.88
+12.32%
|
-5.56
|
| Total Operating Income As Reported |
|
-7.05
-27.92%
|
-5.51
-13.07%
|
-4.88
+12.33%
|
-5.56
|
| EBITDA |
|
-7.01
-11.84%
|
-6.26
-51.30%
|
-4.14
+23.57%
|
-5.42
|
| Normalized EBITDA |
|
-6.42
-20.66%
|
-5.32
-12.85%
|
-4.71
+12.97%
|
-5.42
|
| Reconciled Depreciation |
|
0.23
+17.74%
|
0.19
+18.73%
|
0.16
+13.26%
|
0.14
|
| EBIT |
|
-7.23
-12.02%
|
-6.46
-50.07%
|
-4.30
+22.62%
|
-5.56
|
| Total Unusual Items |
|
-0.59
+37.80%
|
-0.94
-264.69%
|
0.57
+48301.85%
|
-0.00
|
| Total Unusual Items Excluding Goodwill |
|
-0.59
+37.80%
|
-0.94
-264.69%
|
0.57
+48301.85%
|
-0.00
|
| Special Income Charges |
|
-0.60
+53.17%
|
-1.28
|
0.00
|
0.00
|
| Other Special Charges |
|
0.60
-53.17%
|
1.28
|
—
|
—
|
| Net Income |
|
-7.23
-3.44%
|
-6.99
-42.38%
|
-4.91
+30.52%
|
-7.07
|
| Pretax Income |
|
-7.23
-3.44%
|
-6.99
-42.38%
|
-4.91
+30.52%
|
-7.07
|
| Net Non Operating Interest Income Expense |
|
0.41
+176.81%
|
-0.54
+12.00%
|
-0.61
+59.59%
|
-1.51
|
| Interest Expense Non Operating |
|
0.00
-100.00%
|
0.54
-11.97%
|
0.61
-59.65%
|
1.51
|
| Net Interest Income |
|
0.41
+176.81%
|
-0.54
+12.00%
|
-0.61
+59.59%
|
-1.51
|
| Interest Expense |
|
0.00
-100.00%
|
0.54
-11.97%
|
0.61
-59.65%
|
1.51
|
| Interest Income Non Operating |
|
0.41
+129164.47%
|
0.00
+84.88%
|
0.00
-93.15%
|
0.00
|
| Interest Income |
|
0.41
+129164.47%
|
0.00
+84.88%
|
0.00
-93.15%
|
0.00
|
| Other Income Expense |
|
-0.59
+37.30%
|
-0.94
-264.62%
|
0.57
+48324.12%
|
-0.00
|
| Other Non Operating Income Expenses |
|
-0.00
-9597.96%
|
-0.00
-118.49%
|
0.00
|
—
|
| Gain On Sale Of Security |
|
0.01
-96.48%
|
0.34
-41.59%
|
0.57
+48301.85%
|
-0.00
|
| Tax Provision |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-7.23
-3.44%
|
-6.99
-42.38%
|
-4.91
+30.52%
|
-7.07
|
| Net Income From Continuing Operation Net Minority Interest |
|
-7.23
-3.44%
|
-6.99
-42.38%
|
-4.91
+30.52%
|
-7.07
|
| Net Income From Continuing And Discontinued Operation |
|
-7.23
-3.44%
|
-6.99
-42.38%
|
-4.91
+30.52%
|
-7.07
|
| Net Income Continuous Operations |
|
-7.23
-3.44%
|
-6.99
-42.38%
|
-4.91
+30.52%
|
-7.07
|
| Normalized Income |
|
-6.65
-9.88%
|
-6.05
-10.27%
|
-5.48
+22.39%
|
-7.07
|
| Net Income Common Stockholders |
|
-7.24
-2.66%
|
-7.05
-43.60%
|
-4.91
+34.38%
|
-7.48
|
| Diluted EPS |
|
—
|
-5,151.64
+90.45%
|
-53,971.14
+61.06%
|
-138,594.74
|
| Basic EPS |
|
—
|
-5,151.64
+90.45%
|
-53,971.14
+61.06%
|
-138,594.74
|
| Basic Average Shares |
|
—
|
0.00
+1404.40%
|
0.00
+68.52%
|
0.00
|
| Diluted Average Shares |
|
—
|
0.00
+1404.40%
|
0.00
+68.52%
|
0.00
|
| Diluted NI Availto Com Stockholders |
|
-7.24
-2.66%
|
-7.05
-43.60%
|
-4.91
+34.38%
|
-7.48
|
| Other Taxes |
|
—
|
0.00
-100.00%
|
0.00
+43.00%
|
0.00
|
| Preferred Stock Dividends |
|
0.01
-88.80%
|
0.06
|
—
|
0.42
|
| Line Item | Trend | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Total Assets |
|
2.46
-15.61%
|
2.91
|
| Current Assets |
|
1.29
-24.20%
|
1.70
|
| Cash Cash Equivalents And Short Term Investments |
|
1.02
-30.67%
|
1.47
|
| Cash And Cash Equivalents |
|
1.02
-30.67%
|
1.47
|
| Cash Financial |
|
1.02
-30.67%
|
1.47
|
| Receivables |
|
0.01
-28.03%
|
0.02
|
| Accounts Receivable |
|
0.01
-28.54%
|
0.02
|
| Gross Accounts Receivable |
|
0.01
-28.54%
|
0.02
|
| Allowance For Doubtful Accounts Receivable |
|
0.00
|
0.00
|
| Other Receivables |
|
0.00
+83.33%
|
0.00
|
| Prepaid Assets |
|
0.10
-31.59%
|
0.15
|
| Current Deferred Assets |
|
0.10
|
0.00
|
| Restricted Cash |
|
0.01
+0.00%
|
0.01
|
| Other Current Assets |
|
0.04
-16.00%
|
0.05
|
| Total Non Current Assets |
|
1.17
-3.56%
|
1.21
|
| Net PPE |
|
0.00
-46.74%
|
0.00
|
| Gross PPE |
|
0.06
-24.79%
|
0.07
|
| Accumulated Depreciation |
|
-0.05
+23.74%
|
-0.07
|
| Machinery Furniture Equipment |
|
0.06
+0.00%
|
0.06
|
| Other Properties |
|
—
|
0.02
|
| Goodwill And Other Intangible Assets |
|
1.17
-3.44%
|
1.21
|
| Other Intangible Assets |
|
1.17
-3.44%
|
1.21
|
| Total Liabilities Net Minority Interest |
|
3.19
+362.89%
|
0.69
|
| Current Liabilities |
|
3.19
+362.89%
|
0.69
|
| Payables And Accrued Expenses |
|
1.26
+141.66%
|
0.52
|
| Payables |
|
0.76
+64.55%
|
0.46
|
| Accounts Payable |
|
0.76
+65.84%
|
0.46
|
| Other Payable |
|
0.00
-63.09%
|
0.00
|
| Dividends Payable |
|
—
|
0.00
|
| Current Accrued Expenses |
|
0.50
+730.61%
|
0.06
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.36
+113.96%
|
0.17
|
| Current Debt And Capital Lease Obligation |
|
1.13
|
—
|
| Current Debt |
|
1.13
|
—
|
| Other Current Liabilities |
|
0.44
+28.54%
|
0.35
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
| Preferred Securities Outside Stock Equity |
|
—
|
—
|
| Stockholders Equity |
|
-0.73
-132.70%
|
2.23
|
| Common Stock Equity |
|
-0.73
-132.70%
|
2.23
|
| Capital Stock |
|
0.00
-100.00%
|
0.00
|
| Common Stock |
|
0.00
-100.00%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
| Share Issued |
|
0.00
+68.52%
|
0.00
|
| Ordinary Shares Number |
|
0.00
+68.52%
|
0.00
|
| Treasury Shares Number |
|
0.00
|
0.00
|
| Additional Paid In Capital |
|
43.55
+4.71%
|
41.60
|
| Retained Earnings |
|
-44.28
-12.47%
|
-39.37
|
| Total Equity Gross Minority Interest |
|
-0.73
-132.70%
|
2.23
|
| Total Capitalization |
|
-0.73
-132.70%
|
2.23
|
| Working Capital |
|
-1.90
-287.51%
|
1.01
|
| Invested Capital |
|
0.40
-82.13%
|
2.23
|
| Total Debt |
|
1.13
|
—
|
| Net Debt |
|
0.10
|
—
|
| Net Tangible Assets |
|
-1.90
-286.72%
|
1.02
|
| Tangible Book Value |
|
-1.90
-286.72%
|
1.02
|
| Current Notes Payable |
|
1.13
|
0.00
|
| Interest Payable |
|
0.10
|
0.00
|
| Line Of Credit |
|
—
|
—
|
| Preferred Stock Equity |
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-7.16
-35.90%
|
-5.27
-44.55%
|
-3.65
+26.31%
|
-4.95
|
| Cash Flow From Continuing Operating Activities |
|
-7.16
-35.90%
|
-5.27
-44.55%
|
-3.65
+26.31%
|
-4.95
|
| Net Income From Continuing Operations |
|
-7.23
-3.44%
|
-6.99
-42.38%
|
-4.91
+30.52%
|
-7.07
|
| Depreciation Amortization Depletion |
|
0.23
+17.74%
|
0.19
+18.73%
|
0.16
+13.26%
|
0.14
|
| Depreciation |
|
0.00
+104.29%
|
0.00
-10.55%
|
0.00
-65.24%
|
0.00
|
| Amortization Cash Flow |
|
0.22
+17.11%
|
0.19
+19.01%
|
0.16
+15.80%
|
0.14
|
| Depreciation And Amortization |
|
0.23
+17.74%
|
0.19
+18.73%
|
0.16
+13.26%
|
0.14
|
| Amortization Of Intangibles |
|
0.22
+17.11%
|
0.19
+19.01%
|
0.16
+15.80%
|
0.14
|
| Other Non Cash Items |
|
0.11
-94.76%
|
2.03
+240.09%
|
0.60
-54.11%
|
1.30
|
| Stock Based Compensation |
|
0.11
-63.34%
|
0.29
-36.96%
|
0.46
-64.61%
|
1.29
|
| Operating Gains Losses |
|
-0.01
+94.71%
|
-0.22
+61.09%
|
-0.57
-15234.78%
|
0.00
|
| Gain Loss On Investment Securities |
|
-0.01
+96.48%
|
-0.34
+41.58%
|
-0.57
|
—
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Change In Working Capital |
|
-0.36
+36.57%
|
-0.56
-190.59%
|
0.62
+201.10%
|
-0.62
|
| Change In Receivables |
|
-0.01
-256.15%
|
0.01
+587.66%
|
-0.00
+87.87%
|
-0.01
|
| Changes In Account Receivables |
|
-0.01
-256.15%
|
0.01
+587.66%
|
-0.00
+87.87%
|
-0.01
|
| Change In Prepaid Assets |
|
0.02
+105.58%
|
-0.29
-646.42%
|
-0.04
+55.97%
|
-0.09
|
| Change In Payables And Accrued Expense |
|
-0.36
-27.74%
|
-0.28
-142.82%
|
0.66
+228.40%
|
-0.52
|
| Change In Accrued Expense |
|
-0.16
-28.65%
|
-0.13
-128.82%
|
0.44
+409.41%
|
0.09
|
| Change In Payable |
|
-0.20
-27.01%
|
-0.16
-170.89%
|
0.22
+136.58%
|
-0.60
|
| Change In Account Payable |
|
-0.20
-27.01%
|
-0.16
-170.89%
|
0.22
+136.58%
|
-0.60
|
| Investing Cash Flow |
|
-0.20
+36.66%
|
-0.32
-169.35%
|
-0.12
+42.50%
|
-0.21
|
| Cash Flow From Continuing Investing Activities |
|
-0.20
+36.66%
|
-0.32
-169.35%
|
-0.12
+42.50%
|
-0.21
|
| Net PPE Purchase And Sale |
|
-0.02
-320.88%
|
-0.01
|
0.00
-100.00%
|
0.00
|
| Purchase Of PPE |
|
—
|
—
|
—
|
—
|
| Sale Of PPE |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Capital Expenditure |
|
-0.20
+36.66%
|
-0.32
-169.35%
|
-0.12
+42.78%
|
-0.21
|
| Net Intangibles Purchase And Sale |
|
-0.18
+42.44%
|
-0.32
-165.07%
|
-0.12
+42.78%
|
-0.21
|
| Purchase Of Intangibles |
|
—
|
—
|
-0.12
+42.78%
|
-0.21
|
| Net Other Investing Changes |
|
—
|
—
|
—
|
0.00
|
| Financing Cash Flow |
|
18.95
+276.93%
|
5.03
+51.63%
|
3.31
-46.43%
|
6.19
|
| Cash Flow From Continuing Financing Activities |
|
18.95
+276.93%
|
5.03
+51.63%
|
3.31
-46.43%
|
6.19
|
| Net Issuance Payments Of Debt |
|
0.00
+100.00%
|
-0.30
-113.38%
|
2.25
+212.50%
|
-2.00
|
| Issuance Of Debt |
|
—
|
0.00
-100.00%
|
2.25
|
0.00
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-0.30
|
0.00
+100.00%
|
-2.00
|
| Long Term Debt Issuance |
|
—
|
0.00
-100.00%
|
2.25
|
0.00
|
| Long Term Debt Payments |
|
0.00
+100.00%
|
-0.30
|
0.00
+100.00%
|
-2.00
|
| Net Long Term Debt Issuance |
|
0.00
+100.00%
|
-0.30
-113.38%
|
2.25
+212.50%
|
-2.00
|
| Short Term Debt Issuance |
|
—
|
—
|
2.25
|
0.00
|
| Short Term Debt Payments |
|
—
|
—
|
0.00
+100.00%
|
-2.00
|
| Net Short Term Debt Issuance |
|
—
|
—
|
2.25
|
0.00
|
| Net Common Stock Issuance |
|
20.26
+263.49%
|
5.57
+280.95%
|
1.46
-82.89%
|
8.55
|
| Repurchase Of Capital Stock |
|
-1.21
|
0.00
+100.00%
|
-0.00
|
0.00
|
| Proceeds From Stock Option Exercised |
|
2.31
|
0.00
|
0.00
-100.00%
|
8.55
|
| Net Other Financing Charges |
|
-2.41
-93.27%
|
-1.25
-212.89%
|
-0.40
-9.08%
|
-0.37
|
| Changes In Cash |
|
11.58
+2140.35%
|
-0.57
-25.61%
|
-0.45
-143.85%
|
1.03
|
| Beginning Cash Position |
|
0.46
-55.03%
|
1.03
-30.47%
|
1.48
+227.67%
|
0.45
|
| End Cash Position |
|
12.04
+2496.89%
|
0.46
-55.03%
|
1.03
-30.47%
|
1.48
|
| Free Cash Flow |
|
-7.37
-31.73%
|
-5.59
-48.51%
|
-3.77
+26.98%
|
-5.16
|
| Interest Paid Supplemental Data |
|
0.00
-100.00%
|
0.01
+22.11%
|
0.01
|
—
|
| Income Tax Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
—
|
| Change In Interest Payable |
|
—
|
0.00
+100.00%
|
-0.01
-103.08%
|
0.20
|
| Common Stock Issuance |
|
20.26
+263.49%
|
5.57
+280.95%
|
1.46
-82.89%
|
8.55
|
| Issuance Of Capital Stock |
|
20.26
+208.19%
|
6.57
+349.00%
|
1.46
-82.88%
|
8.55
|
| Net Preferred Stock Issuance |
|
-1.21
-221.36%
|
1.00
|
0.00
|
0.00
|
| Preferred Stock Issuance |
|
0.00
-100.00%
|
1.00
+99900.00%
|
0.00
|
0.00
|
| Preferred Stock Payments |
|
-1.21
|
0.00
+100.00%
|
-0.00
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-19 View
- 10-K2026-03-18 View
- 8-K2026-01-13 View
- 8-K2026-01-09 View
- 42025-12-01 View
- 10-Q2025-11-12 View
- 8-K2025-10-14 View
- 42025-09-03 View
- 8-K2025-09-03 View
- 10-Q2025-08-14 View
- 8-K2025-07-21 View
- 8-K2025-07-07 View
- 8-K2025-06-20 View
- 10-Q2025-05-15 View
- 8-K2025-04-23 View
- 10-K2025-04-09 View
- 8-K2025-03-28 View
- 8-K2025-03-13 View
- 8-K2025-03-06 View
- 8-K2025-02-28 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|